阿立哌唑/利培酮联合多奈哌齐治疗阿尔茨海默病的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 阿立哌唑/利培酮联合多奈哌齐治疗阿尔茨海默病的临床观察
TITLE:
摘要: 目的:观察阿立哌唑/利培酮联合多奈哌齐治疗阿尔茨海默病的疗效及安全性。方法:选取阿尔茨海默病患者46例,按随机数字表法分为对照组(24例)和试验组(22例)。两组患者均给予多奈哌齐5 mg,qd,基础治疗,在此基础上对照组患者给予利培酮初始剂量1 mg,并根据病情逐渐增加至2~4 mg,qd;试验组患者给予阿立哌唑10 mg,qd。两组患者均治疗8周。采用阿尔茨海默病病理行为评定量表(BEHAV-AD)及社会功能评定量表(PSP)对两组患者治疗前及治疗后2、4、6、8周的各项指标进行评分,并比较两组患者副反应量表(TESS)评分。结果:治疗后,两组患者BEHAV-AD评分均显著下降,试验组下降更为显著,差异有统计学意义(P<0.05);治疗后,试验组患者行为紊乱、攻击行为、谵妄、抑郁、焦虑评分显著低于对照组,差异有统计学意义(P<0.05),偏执、幻觉评分比较,差异无统计学意义(P>0.05);治疗后两组患者PSP评分均显著升高,且试验组升高更为显著,差异有统计学意义(P<0.05)。试验组患者毒副反应评分显著低于对照组,差异有统计学意义(P<0.05)。 结论:阿立哌唑/利培酮联用多奈哌齐对阿尔茨海默病均有效,而阿立哌唑效更为确切,且安全性较好。
ABSTRACT: OBJECTIVE: To observe therapeutic efficacy and safety of aripirazle or risperidone combined with donepezil in the treatment of Alzheimer disease. METHODS: 46 patients with alzheimer disease were randomly divided into control group (n=24) and experiment group(n=22). Both groups received routine treatment, donepezil 5 mg, qd; control group was additionally given risperidone 1 mg, increasing to 2-4 mg, qd, according to disease condition; experiment group was additionally  given aripirazle 10 mg, qd. Both groups were given 8 weeks of treatment. BEHAV-AD score and PSP score of each indicators in 2 groups were recorded before treatment, 2, 4, 6 and 8 weeks after treatment, and TESS score were compared between 2 groups. RESULTS: After treatment, BEHAV-AD score of 2 groups decreased significantly, especially in experiment group,  with statistical significance (P<0.05). After treatment, the score for aggressive behavior, conduct disorder, depress and anxiety in experiment group were much lower than that of control group, with statistical significance (P<0.05); there was no statistical significance in crankiness, hallucination and deliration score (P>0.05). After treatment,PSP score of 2 groups elevated markedty, the test group increased more significantly,with statistical significance(P<0.05) ADR score of experiment group was significantly lower than that of control group, with statistical significance (P<0.05). CONCLUSIONS: Both aripirazle or risperidone combined with donepezil is effective for Alzheimer disease, and aripirazle combined with donepezil shows more definite efficacy and better safety.
期刊: 2016年第27卷第2期
作者: 雷四英
AUTHORS: LEI Siying
关键字: 阿立哌唑;利培酮;多奈哌齐;阿尔茨海默病;疗效;安全性
KEYWORDS: Aripirazle; Risperidone; Donepezil; Alzheimer disease; Efficacy; Safety
阅读数: 549 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!